Low molecular weight heparin in vein thrombosis
Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S
Record ID 32005000625
Spanish
Authors' objectives:
The objective of this evaluation is to analyze the efficacy of low molecular weight heparin (LMWH) compared with dicumarinic drugs in the prevention and treatment of deep vein thrombosis an pulmonary embolism.
Authors' results and conclusions:
The evidence published so far shows that LMWHs are not better than dicumarinic drugs for these indications in the short and long term, with the possible exception of programmed knee surgery, for which their could be some potential benefit.
Authors' recommendations:
At present, its use could be justified as initial anticoagulation therapy, both for prophylaxis and treatment of thromboembolic disease, replacing unfractioned heparin. In addition, it should not be used for more than ten days. The potential benefits would be shorter hospital stay, fewer laboratory controls and easiness of administration.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
http://www.iecs.org.ar/
Year Published:
2003
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Anticoagulants
- Heparin, Low-Molecular-Weight
- Venous Thrombosis
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.